ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

ClinicalTrials.gov ID: NCT03061812

Public ClinicalTrials.gov record NCT03061812. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)

Study identification

NCT ID
NCT03061812
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
444 participants

Conditions and interventions

Interventions

  • Dexamethasone Drug
  • Rovalpituzumab tesirine Drug
  • Topotecan Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 10, 2017
Primary completion
Feb 11, 2020
Completion
Feb 11, 2020
Last update posted
Feb 22, 2021

2017 – 2020

United States locations

U.S. sites
31
U.S. states
21
U.S. cities
31
Facility City State ZIP Site status
Clearview Cancer Institute /ID# 155873 Huntsville Alabama 35805
Mitchell Cancer Institute /ID# 158151 Mobile Alabama 36604
Carti /Id# 156982 Little Rock Arkansas 72205
Highlands Oncology Group /ID# 155902 Springdale Arkansas 72762
Cedars-Sinai Medical Center /ID# 157102 Beverly Hills California 90211
Moore UC San Diego Cancer Center /ID# 156965 La Jolla California 92093
Los Angeles Hematology Oncolog /ID# 155879 Los Angeles California 90017
University of California, Davis Comprehensive Cancer Center /ID# 157001 Sacramento California 95817
St Jude Hospital dba St Joseph /ID# 155899 Santa Rosa California 95403
Icri /Id# 157090 Whittier California 90603
Christiana Care Health Service /ID# 158171 Newark Delaware 19713
Cancer Specialists of North Florida - Southpoint /ID# 155828 Jacksonville Florida 32256
Georgia Cancer Center /ID# 160206 Atlanta Georgia 30342
St. Luke's Mountain States Tumor Institute - Meridian /ID# 164550 Meridian Idaho 83712
NorthShore University HealthSystem - Evanston Hospital /ID# 157054 Evanston Illinois 60201
Ingalls Memorial Hosp /ID# 155871 Harvey Illinois 60426
Goshen Center for Cancer Care /ID# 155946 Goshen Indiana 46526
University of Louisville /ID# 155947 Louisville Kentucky 40202
Ochsner Clinic Foundation /ID# 160807 Baton Rouge Louisiana 70836-6455
Dana-Farber Cancer Institute /ID# 160210 Boston Massachusetts 02215
Sparrow Regional Cancer Center, Sparrow Health System /ID# 157021 Lansing Michigan 48912
Nebraska Hematology Oncology /ID# 155900 Lincoln Nebraska 68506
Gabrail Cancer Center Research /ID# 155920 Canton Ohio 44718
Oregon Health and Science University /ID# 157055 Portland Oregon 97239
UPMC Hillman Cancer Ctr /ID# 164403 Pittsburgh Pennsylvania 15232
Univ Medical Ctr Brackenridge /ID# 156967 Austin Texas 78701
UT Southwestern Medical Center /ID# 158150 Dallas Texas 75390-7208
University of Vermont Medical Center /ID# 162317 Burlington Vermont 05401-1473
University of Washington /ID# 162626 Seattle Washington 98109
Medical Oncology Associates /ID# 156856 Spokane Washington 99208
West Virginia Univ School Med /ID# 155872 Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 164 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03061812, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 22, 2021 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03061812 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →